CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer

被引:23
|
作者
Kim, Se Hyun [1 ,2 ]
Park, Kyu Hyun [3 ]
Shin, Sang Joon [3 ]
Lee, Kang Young [4 ]
Kim, Tae Il [3 ]
Kim, Nam Kyu [4 ]
Rha, Sun Young [3 ]
Ahn, Joong Bae [2 ,3 ]
机构
[1] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea
[2] Yonsei Univ, Grad Sch, Dept Med, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea
关键词
Colorectal carcinoma; CpG island methylator phenotype; DNA methylation; Wnt pathway; PROMOTER METHYLATION; CHEMOTHERAPY; MUTATION;
D O I
10.3349/ymj.2018.59.5.588
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Dysregulation of the Wnt pathway is a crucial step in the tumorigenesis of colorectal cancer (CRC). This study aimed to determine whether DNA methylation of Wnt pathway genes helps predict treatment response and survival in patients with meta-static or recurrent CRC. Materials and Methods: We retrospectively collected primary tumor tissues from 194 patients with metastatic or recurrent CRC. Pyrosequencing was used to examine the methylation of 10 CpG island loci in DNA extracted from formalin-fixed paraffin-embedded specimens. To elucidate the predictive role of DNA methylation markers, Kaplan-Meier survival estimation and Cox regression were performed for progression-free survival and overall survival (OS). Results: The methylation frequencies of the 10 genes analyzed (p16, p19, MINT1, MINT2, MINT31, hMLH1, DKK3, WNT5A, AXIN2, and TFAP2E) were 47.9%, 10.8%, 21.1%, 16.0%, 20.6%, 0.5%, 53.1%, 32.0%, 2.6%, and 2.1%, respectively. We divided patients into three groups based on the number of methylated genes (group 1, no methylation n=38; group 2, 1-2 methylations n 2; group 3, 3 or more methylations n=64). Among patients treated with palliative chemotherapy (n=167), median OSs of groups 1, 2, and 3 were 39.1, 39.7, and 29.1 months, respectively (log rank p=0.013). After adjustment, number of methylations was identified as an independent poor prognostic factor (0-2 methylated vs. 1.3 methylated: hazard ratio, 1.72; 95% confidence interval, 1.16-2.56, p=0.007). Conclusion: This study suggests that methylation of Wnt pathway genes, in addition to known CpG island methylator phenotype markers, may help predict treatment outcome and survival in patients with CRC.
引用
收藏
页码:588 / 594
页数:7
相关论文
共 50 条
  • [21] Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
    Shailesh Mahesh Advani
    Pragati Shailesh Advani
    Derek W. Brown
    Stacia M. DeSantis
    Krittiya Korphaisarn
    Helena M. VonVille
    Jan Bressler
    David S. Lopez
    Jennifer S. Davis
    Carrie R. Daniel
    Amir Mehrvarz Sarshekeh
    Dejana Braithwaite
    Michael D. Swartz
    Scott Kopetz
    BMC Cancer, 19
  • [22] Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer
    Ichimura, Norihisa
    Shinjo, Keiko
    An, Byonggu
    Shimizu, Yasuhiro
    Yamao, Kenji
    Ohka, Fumiharu
    Katsushima, Keisuke
    Hatanaka, Akira
    Tojo, Masayuki
    Yamamoto, Eiichiro
    Suzuki, Hiromu
    Ueda, Minoru
    Kondo, Yutaka
    CANCER PREVENTION RESEARCH, 2015, 8 (08) : 702 - 711
  • [23] CpG Island Methylator Phenotype in Colorectal Cancers Comparison of the New and Classic CpG Island Methylator Phenotype Marker Panels
    Lee, Sun
    Cho, Nam-Yun
    Yoo, Eun Joo
    Kim, Jung Ho
    Kang, Gyeong Hoon
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2008, 132 (10) : 1657 - 1665
  • [24] Aberrant TET1 methylation closely associated with CpG island methylator phenotype in colorectal cancer
    Ichimura, Norihisa
    Shinjo, Keiko
    Ohka, Fumiharu
    Katsushima, Keisuke
    Hatanaka, Akira
    Tojo, Masayuki
    Shimizu, Yasuhiro
    Yamamoto, Eiichiro
    Suzuki, Hiromu
    Kondo, Yutaka
    CANCER RESEARCH, 2015, 75
  • [25] CpG island methylator phenotype (CIMP) in Puerto Rican Hispanic colorectal cancer patients
    Bernabe-Dones, Raul D.
    Cruz-Correa, Marcia R.
    Castro, Cristina I.
    Lacourt, Mercedes Y.
    Rodriguez, Heriberto
    Castillo, Xiomara M.
    Marcano, Isabel C.
    Nunez, Cristina
    Baez, Noelia
    Lozada, Maria E.
    Maldonado, Meredid S.
    Oliveras, Luis F.
    Cardona, Alberto
    CANCER RESEARCH, 2011, 71
  • [26] CPG ISLAND METHYLATOR PHENOTYPE IS ASSOCIATED WITH THE EFFICACY OF CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Shimodaira, H.
    Zhang, X.
    Komine, K.
    Takahashi, M.
    Takahashi, S.
    Ishioka, C.
    ANNALS OF ONCOLOGY, 2014, 25
  • [27] Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
    Advani, Shailesh Mahesh
    Advani, Pragati Shailesh
    Brown, Derek W.
    DeSantis, Stacia M.
    Korphaisarn, Krittiya
    VonVille, Helena M.
    Bressler, Jan
    Lopez, David S.
    Davis, Jennifer S.
    Daniel, Carrie R.
    Sarshekeh, Amir Mehrvarz
    Braithwaite, Dejana
    Swartz, Michael D.
    Kopetz, Scott
    BMC CANCER, 2019, 19 (01)
  • [28] Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae, Jeong Mo
    Rhee, Ye-Young
    Kim, Kyung Ju
    Wen, Xianyu
    Song, Young Seok
    Cho, Nam-Yun
    Kim, Jung Ho
    Kang, Gyeong Hoon
    HUMAN PATHOLOGY, 2016, 47 (01) : 85 - 94
  • [29] CpG island methylator phenotype and patients with multiple colorectal cancers.
    Grady, WM
    Markowitz, S
    Willis, J
    GASTROENTEROLOGY, 2000, 118 (04) : A46 - A46
  • [30] CpG island methylator phenotype in bladder cancer
    Chung, Woonbok
    Bondaruk, Jolanta
    Zhang, Nianxiang
    Jelinek, Jaroslav
    Estecio, Marcos
    Liang, Shoudan
    Czerniak, Bogdan
    Issa, Jean-Pierre J.
    CANCER RESEARCH, 2012, 72